$926 Million is the total value of Rhenman & Partners Asset Management AB's 94 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 56.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VRTX | Buy | VERTEX PHARMACEUTICALS INC | $39,918,000 | +45.9% | 137,500 | +19.6% | 4.31% | +12.5% |
| UNH | Buy | UNITEDHEALTH GROUP INC | $30,970,000 | +55.2% | 105,000 | +31.2% | 3.35% | +19.7% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $23,435,000 | +50.0% | 190,000 | +2.8% | 2.53% | +15.7% |
| BMY | Buy | BRISTOL MYERS SQUIBB CO | $22,344,000 | +14.5% | 380,000 | +8.6% | 2.41% | -11.7% |
| NVCR | Buy | NOVOCURE LTD | $22,238,000 | -8.3% | 375,000 | +4.2% | 2.40% | -29.3% |
| HUM | Buy | HUMANA INC | $21,326,000 | +50.9% | 55,000 | +22.2% | 2.30% | +16.4% |
| ALXN | Buy | ALEXION PHARMACEUTICALS INC | $21,326,000 | +48.4% | 190,000 | +18.8% | 2.30% | +14.5% |
| CI | Buy | CIGNA CORP NEW | $20,642,000 | +11.0% | 110,000 | +4.8% | 2.23% | -14.4% |
| GILD | New | GILEAD SCIENCES INC | $17,696,000 | – | 230,000 | +100.0% | 1.91% | – |
| LLY | Buy | LILLY ELI & CO | $17,239,000 | +24.3% | 105,000 | +5.0% | 1.86% | -4.2% |
| ABT | Buy | ABBOTT LABS | $16,915,000 | +26.1% | 185,000 | +8.8% | 1.83% | -2.8% |
| AXNX | Buy | AXONICS MODULATION TECH INC | $16,502,000 | +39.7% | 470,000 | +1.1% | 1.78% | +7.7% |
| BHVN | Buy | BIOHAVEN PHARMACTL HLDG CO L | $15,353,000 | +222.3% | 210,000 | +50.0% | 1.66% | +148.7% |
| JAZZ | Buy | JAZZ PHARMACEUTICALS PLC | $15,120,000 | +26.3% | 137,032 | +14.2% | 1.63% | -2.6% |
| GH | Buy | GUARDANT HEALTH INC | $15,009,000 | +23.2% | 185,000 | +5.7% | 1.62% | -5.0% |
| CNC | Buy | CENTENE CORP DEL | $14,895,000 | +43.3% | 234,378 | +33.9% | 1.61% | +10.4% |
| XLRN | Buy | ACCELERON PHARMA INC | $14,767,000 | +134.7% | 155,000 | +121.4% | 1.60% | +81.0% |
| COO | Buy | COOPER COS INC | $11,346,000 | +71.5% | 40,000 | +66.7% | 1.23% | +32.3% |
| LIVN | Buy | LIVANOVA PLC | $10,589,000 | +23.2% | 220,000 | +15.8% | 1.14% | -5.1% |
| LVGO | New | LIVONGO HEALTH INC | $9,399,000 | – | 125,000 | +100.0% | 1.02% | – |
| EW | Buy | EDWARDS LIFESCIENCES CORP | $8,293,000 | -22.9% | 120,000 | +110.5% | 0.90% | -40.5% |
| BAX | New | BAXTER INTL INC | $8,180,000 | – | 95,000 | +100.0% | 0.88% | – |
| REGN | New | REGENERON PHARMACEUTICALS | $7,796,000 | – | 12,500 | +100.0% | 0.84% | – |
| BLUE | Buy | BLUEBIRD BIO INC | $6,580,000 | +113.7% | 107,797 | +60.9% | 0.71% | +65.0% |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $5,389,000 | +101.2% | 165,000 | +65.0% | 0.58% | +55.2% |
| BDX | Buy | BECTON DICKINSON & CO | $5,025,000 | +56.2% | 21,000 | +50.0% | 0.54% | +20.4% |
| AIMT | Buy | AIMMUNE THERAPEUTICS INC | $4,762,000 | +100.2% | 285,000 | +72.7% | 0.51% | +54.4% |
| RDUS | Buy | RADIUS HEALTH INC | $4,523,000 | +17.9% | 331,826 | +12.5% | 0.49% | -8.9% |
| MGTX | Buy | MEIRAGTX HOLDINGS PLC | $3,756,000 | +13.5% | 300,000 | +21.8% | 0.41% | -12.5% |
| MYOV | New | MYOVANT SCIENCES LTD | $3,093,000 | – | 150,000 | +100.0% | 0.33% | – |
| SWAV | New | SHOCKWAVE MED INC | $2,842,000 | – | 60,000 | +100.0% | 0.31% | – |
| QCOM | New | QUALCOMM INC | $217,000 | – | 2,381 | +100.0% | 0.02% | – |
| JPM | New | JPMORGAN CHASE & CO | $162,000 | – | 1,723 | +100.0% | 0.02% | – |
| DIS | New | DISNEY WALT CO | $149,000 | – | 1,338 | +100.0% | 0.02% | – |
| PFE | New | PFIZER INC | $147,000 | – | 4,508 | +100.0% | 0.02% | – |
| BUD | New | ANHEUSER BUSCH INBEV SA/NVsponsored adr | $138,000 | – | 2,806 | +100.0% | 0.02% | – |
| NLOK | New | NORTONLIFELOCK INC | $137,000 | – | 6,926 | +100.0% | 0.02% | – |
| WFC | New | WELLS FARGO CO NEW | $135,000 | – | 5,272 | +100.0% | 0.02% | – |
| HAL | New | HALLIBURTON CO | $108,000 | – | 8,299 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-07-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.